SM
OPNT

SG3 Management’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

SG3 Management’s Portfolio OPNT Stock Details OPNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-16,084
Closed -$345K – 959
2022
Q1 		$345K Buy
+16,084
New +$426K 0.01% 674

Other funds holding OPNT

HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

SG3 Management's OPNT Position: Q2 2022 in Review

SG3 Management sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q2 2022, closing a stake of 16,084 shares — an estimated $345K sold.

SG3 Management first reported a position in OPNT in Q1 2022 and held it in 1 quarter. The position peaked at $345K in Q1 2022. 33 funds tracked by Wall St. Rank hold OPNT as of Q2 2022.

  • SG3 Management reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • SG3 Management sold 16,084 Opiant Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $345K.
  • SG3 Management first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • SG3 Management's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $345K in Q1 2022.
  • 33 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on SG3 Management's 13F filing for Q2 2022, filed 15 Aug 2022.